rosiglitazone has been researched along with Coronary Artery Disease in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (40.74) | 29.6817 |
| 2010's | 16 (59.26) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arsenault, BJ; Bertrand, OF; Brassard, P; Costerousse, O; Després, JP; Laberge, AS; Piché, ME; Poirier, P | 1 |
| Gerstein, HC | 1 |
| Bach, RG; Brooks, MM; Donner, TW; Frye, RL; Garber, A; Genuth, S; Kelsey, SF; Kennedy, L; Lombardero, M; Monrad, ES; Pop-Busui, R | 2 |
| Ala-Korpela, M; Badeau, RM; Honka, MJ; Kangas, AJ; Lautamäki, R; Nuutila, P; Soininen, P; Stewart, M | 1 |
| Abdullah, SM; Ayers, CR; de Lemos, JA; Gore, MO; Grinsfelder, DB; Khera, A; McGuire, DK; Neeland, IJ; Pandey, A; Salahuddin, UI; See, R | 1 |
| Desch, S; Niebauer, J; Rastan, A; Schmidt, A; Schuler, G; Sixt, S; Sonnabend, M | 1 |
| Forst, T; Löbig, M; Marx, N; Pfützner, A; Seidel, D; Walcher, D | 1 |
| Cannon, CP; Fitzgerald, PJ; Gerstein, HC; Kolatkar, NS; Kravitz, BG; Nesto, RW; Ratner, RE; Serruys, PW; Van Es, GA; Zalewski, A | 1 |
| Chandrashekhar, Y; Finn, AV; Narula, J | 1 |
| Cannon, CP; Fitzgerald, PJ; García-García, HM; Gerstein, HC; Huang, C; Kolatkar, NS; Kravitz, BG; Miller, DM; Nesto, RW; Ratner, RE; Serruys, PW; van Es, GA | 1 |
| Alméras, N; Angel, J; Batalla, N; Bertrand, OF; Costerousse, O; De Larochellière, R; Després, JP; Dzavik, V; Natarajan, M; Poirier, P; Rinfret, S; Rodés-Cabau, J; Roy, L; Title, LM | 1 |
| Blüher, M; de Waha, S; Desch, S; Eitel, I; Niebauer, J; Sareban, M; Schuler, G; Sixt, S; Sonnabend, M; Thiele, H | 1 |
| Fu, X; Han, Y; He, X; Heng, CK; Huang, C; Li, N; Shi, X; Wu, Y; Zhao, Y | 1 |
| Gautier, JF; Lesven, S; Maréchaud, R | 1 |
| Brugaletta, S; García-García, HM; Garg, S; Huang, C; Kolatkar, NS; Kravitz, BG; Miller, DM; Morocutti, G; Nesto, RW; Ratner, RE; Serruys, PW | 1 |
| Bakris, G; de Guzman, E; Lazich, I; Oliva, R; Patel, A; Sarafidis, P | 1 |
| Addabbo, F; Montagnani, M; Potenza, MA; Sgarra, L | 1 |
| Choy-Shan, A; Danoff, A; Donnino, R; Grossi, E; Lorin, JD; Schwartzbard, AZ; Sedlis, SP; Shah, B; Zinn, A | 1 |
| Froehlich, J; Hombach, V; Ittner, J; Koenig, W; Marx, N; Scharnagl, H; Schmidt, A; Siam, L; Wierse, G | 1 |
| Plosker, SM | 1 |
| Froehlich, J; Hombach, V; Imhof, A; Ittner, J; Koenig, W; Maerz, W; Marx, N; Schmidt, A; Siam, L; Wierse, G | 1 |
| Cowan, D; Kaski, JC; Sidhu, JS | 1 |
| Kaposzta, Z; Kaski, JC; Markus, HS; Sidhu, JS | 1 |
| Abchee, AB; Alam, S; Ayach, K; Dakik, HA; Mehio-Sibai, A; Nasrallah, A; Sawaya, J; Sibai, T; Skouri, HN; Wehbeh, C | 1 |
| Joshi, SR; Mohan, V | 1 |
| Chilton, R; Sulistio, MS; Thukral, N; Zion, A | 1 |
4 review(s) available for rosiglitazone and Coronary Artery Disease
| Article | Year |
|---|---|
The impacts of thiazolidinediones on circulating C-reactive protein levels in different diseases: a meta-analysis.
Topics: C-Reactive Protein; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
Treatment of type 2 diabetes: New clinical studies and effects of GLP-1 on macrovascular complications.
Topics: Animals; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucagon-Like Peptide 1; Heart Diseases; Humans; Hypoglycemic Agents; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
Polycystic ovary syndrome and insulin resistance.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Polycystic Ovary Syndrome; Prevalence; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; United States; Women's Health | 2003 |
PPARgamma agonists and coronary atherosclerosis.
Topics: Animals; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Nonesterified; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; PPAR gamma; Randomized Controlled Trials as Topic; Rosiglitazone; Stents; Thiazolidinediones; Triglycerides | 2008 |
15 trial(s) available for rosiglitazone and Coronary Artery Disease
| Article | Year |
|---|---|
Rosiglitazone lowers resting and blood pressure response to exercise in men with type 2 diabetes: A 1-year randomized study.
Topics: Aged; Blood Glucose; Blood Pressure; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Exercise; Exercise Test; Exercise Tolerance; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; PPAR gamma; Rest; Rosiglitazone | 2018 |
Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Topics: Aged; Angioplasty; Comorbidity; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Risk Factors; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome | 2013 |
Systemic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPARγ agonist.
Topics: Aged; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glutamine; Humans; Hypoglycemic Agents; Lactic Acid; Lipoproteins; Male; Middle Aged; Myocardium; PPAR gamma; Rosiglitazone; Thiazolidinediones; Time Factors | 2014 |
Effect of treatment with rosiglitazone on high-sensitivity cardiac troponin levels among patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Risk Factors; Rosiglitazone; Thiazolidinediones; Troponin | 2016 |
Exercise training but not rosiglitazone improves endothelial function in prediabetic patients with coronary disease.
Topics: Aged; Blood Flow Velocity; Coronary Artery Disease; Endothelium, Vascular; Exercise Therapy; Exercise Tolerance; Female; Forearm; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Prediabetic State; Rosiglitazone; Thiazolidinediones; Uric Acid; Vasodilation | 2008 |
Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics.
Topics: Adult; Aged; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Double-Blind Method; Female; Glipizide; Humans; Hypoglycemic Agents; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones; Ultrasonography, Interventional | 2008 |
Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiov
Topics: Adult; Aged; Aged, 80 and over; Coronary Artery Disease; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Endpoint Determination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Ultrasonography, Interventional | 2010 |
Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial.
Topics: Aged; Atherosclerosis; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Risk; Rosiglitazone; Saphenous Vein; Thiazolidinediones | 2010 |
Effects of physical exercise versus rosiglitazone on endothelial function in coronary artery disease patients with prediabetes.
Topics: Blood Glucose; Brachial Artery; Coronary Artery Disease; Endothelium, Vascular; Exercise Therapy; Fasting; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Prediabetic State; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2010 |
Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History).
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug-Eluting Stents; Female; Glipizide; Humans; Hyperplasia; Hypoglycemic Agents; Male; Metals; Middle Aged; Neointima; Predictive Value of Tests; Prospective Studies; Prosthesis Design; Rosiglitazone; Stents; Thiazolidinediones; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study.
Topics: Adiponectin; Adult; Aged; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C-Reactive Protein; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation; Isoprostanes; Lipids; Male; Malondialdehyde; Metabolic Syndrome; Middle Aged; Oxidative Stress; Rosiglitazone; Simvastatin; Thiazolidinediones | 2012 |
Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease.
Topics: Adult; Aged; Anti-Inflammatory Agents; Apolipoproteins; Biomarkers; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 8; Matrix Metalloproteinase 9; Middle Aged; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Serum Amyloid A Protein; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2003 |
Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease.
Topics: Adult; Aged; Biomarkers; Blood Glucose; CD40 Ligand; Coronary Artery Disease; Diabetes Mellitus, Type 2; E-Selectin; Female; Fibrinolytic Agents; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Receptors, Cytoplasmic and Nuclear; Receptors, Interleukin-2; Reference Values; Rosiglitazone; Solubility; Thiazoles; Thiazolidinediones; Time; Transcription Factors; Treatment Outcome; Vasodilator Agents | 2003 |
The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients.
Topics: Aged; Anti-Inflammatory Agents; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Diabetes Mellitus; Endothelium, Vascular; Female; Fibrinogen; Humans; Insulin Resistance; Male; Middle Aged; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Vasodilator Agents | 2003 |
Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Carotid Artery Diseases; Carotid Artery, Common; Cohort Studies; Coronary Artery Disease; Disease Progression; Double-Blind Method; Drug Synergism; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperplasia; Insulin Resistance; Lipids; Male; Middle Aged; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Ultrasonography; Weight Gain | 2004 |
8 other study(ies) available for rosiglitazone and Coronary Artery Disease
| Article | Year |
|---|---|
Rosiglitazone and cardiovascular outcomes: is there a clear answer?
Topics: Angioplasty; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Male; Rosiglitazone; Thiazolidinediones | 2013 |
Response to letter regarding article, "rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial".
Topics: Angioplasty; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2014 |
Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with type 2 diabetes and coronary artery disease.
Topics: Adiponectin; Aged; Coronary Artery Disease; Cytokines; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; PPAR gamma; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2008 |
Seeking alternatives to Hard End Points: is imaging the best APPROACH?
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Ultrasonography, Interventional | 2010 |
Determinants of evolving metabolic and cardiovascular benefit/risk profiles of rosiglitazone therapy during the natural history of diabetes: molecular mechanisms in the context of integrated pathophysiology.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Disease Progression; Endothelium, Vascular; Humans; Hypoglycemic Agents; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones | 2012 |
Effect of rosiglitazone on survival in patients with diabetes mellitus treated for coronary artery disease.
Topics: Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; New York City; Proportional Hazards Models; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Rosiglitazone; Survival Rate; Thiazolidinediones; Time Factors; Treatment Outcome | 2012 |
Prevalence of coronary artery calcium among asymptomatic men and women in a developing country: comparison with the USA data.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Calcinosis; Calcium; Comorbidity; Coronary Artery Disease; Coronary Vessels; Developing Countries; Diabetes Mellitus, Type 2; Female; Humans; Hypercholesterolemia; Hypertension; Hypertriglyceridemia; Lebanon; Male; Middle Aged; Prevalence; Risk Factors; Rosiglitazone; Smoking; Thiazolidinediones; Tomography, X-Ray Computed; United States | 2005 |
The rosiglitazone controversy: the Indian perspective.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Evaluation; Humans; Hypoglycemic Agents; India; Meta-Analysis as Topic; Rosiglitazone; Thiazolidinediones | 2007 |